Odensomab 60mg Injection consists of the active ingredient Denosumab. It is a medication used to treat osteoporosis, characterized by weakened bones. It is also prescribed to prevent bone complications in patients with certain types of cancer, such as multiple myeloma and bone metastases. Odensomab 60mg Injection works by inhibiting a protein called RANK ligand, which plays a role in the breakdown of bone tissue. Studies proved it can significantly increase bone density, reducing fracture risk in postmenopausal women with osteoporosis and patients with cancer-related bone loss. Close monitoring of renal function may be necessary for patients with moderate renal impairment.

Odensomab 60mg Injection should not be used in individuals with known hypersensitivity or allergic reactions to its components. Adequate calcium and vitamin D supplementation is required to ensure during the treatment. It is not approved for use in children and adolescents. Its safety and effectiveness in pediatric populations have not been established, so its use is contraindicated in individuals under 18. This medication should be used cautiously in individuals with pre-existing hypoparathyroidism, characterized by low parathyroid hormone levels.